At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 119 enrolled
Drug / intervention
eculizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
In Brief
A Phase 3 clinical trial evaluating eculizumab for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder. Completed, enrolled 119 participants across 69 sites in 20 countries.
Detailed Summary
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Canada, Colombia, Croatia, Czechia, Denmark, Germany, Hong Kong, Italy, Japan, Malaysia, Russia, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartJan 2015
Primary CompletionJul 2021
TodayJul 2026
First PostedDec 6, 2013
Enrollment StartJan 12, 2015
Primary CompletionJul 12, 2021
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 12.6 years ago
Interventions
eculizumabbiological